Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells.
Arachidonic acid (AA) and its metabolites are intimately linked to carcinogenesis. Inhibitors of AA metabolic enzymes have demonstrated anti-carcinogenic effects in vivo and induce apoptosis of many cancer cell lines in vitro. The mechanism by which AA influences carcinogenesis, however, remains unresolved. The current study explores the growth inhibitory potential of Triacsin C, PLT-98625, and NS-398 which inhibit three distinct metabolic enzymes that control intracellular AA levels: fatty acid coenzyme-A ligase 4 (FACL-4), coenzyme-A independent transacylase (CoA-IT), and cyclooxygenase (COX), respectively. Results reveal the anti-proliferative effects of these inhibitors in a number of human cancer cell lines. Further studies in the SK-MES-1 cell line demonstrate that all three inhibitors induce accumulation of unesterified AA which correlates with induction of apoptosis. Addition of exogenous AA also induces apoptosis. Furthermore, in combination, these inhibitors act cooperatively to induce AA accumulation which correlates to a synergistic reduction in cell viability. Taken together, these results suggest that accumulation of unesterified AA is a common mechanism in the induction of cancer cell apoptosis by various inhibitors of AA metabolism, confirm that previously described AA remodeling pathways are valid in cancer cells, and indicate that combination treatment strategies utilizing these inhibitors may represent a novel approach to blocking cancer cell growth. Further study is required to determine the downstream pathway(s) whereby high cellular burdens of unesterified AA promote apoptosis.
Monjazeb
Arta M
AM
Department of Cancer Biology, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157, USA.
High
Kevin P
KP
Koumenis
Constantinos
C
Chilton
Floyd H
FH
D000217:Acyltransferases / Q000037:antagonists & inhibitors; D017209:Apoptosis / Q000187:drug effects*; D016718:Arachidonic Acid / Q000378:metabolism* / Q000494:pharmacology; D053148:Caspase 3; D020169:Caspases / Q000502:physiology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003066:Coenzyme A Ligases / Q000037:antagonists & inhibitors; D004357:Drug Synergism; D006367:HeLa Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D009578:Nitrobenzenes / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D014226:Triazenes / Q000494:pharmacology*
D007093:Imidazoles; D009578:Nitrobenzenes; D009943:Organophosphorus Compounds; C093303:SK&F 98625; D013449:Sulfonamides; D014226:Triazenes; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D016718:Arachidonic Acid; C034613:triacsin C; D000217:Acyltransferases; C039766:arachidonyl transacylase; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D003066:Coenzyme A Ligases